AI Summary & Key Takeaways
AI InsightOur results showed that increasing concentrations of neopterin does not have any significant effects on the cytotoxicity while as expected the three other agents decrease the viability of all subjected cell lines.
📌 3 Key Takeaways
Abstract
Hepatocellular carcinoma (HCC) is inflammation-related cancer and the 4 th leading cause of death globally . Neopterin is an instant biomarker of the cellular immune response and belongs to the pteridine class. The levels of neopterin are believed to be very closely linked with the tumor size in patients with HCC. Various studies have proven that neopterin can modulate the cellular oxidant-antioxidant balance, thus causing cell toxicity. In this study, we investigated the cytotoxic effects of neopterin alone and in combination with two of the known cytotoxic agents of doxorubicin and cisplatin together with vitamin C, a well-known antioxidant agent. SNU-449, Hep3B, Mahlavu, and PLC/PRF/5 HCC cell lines were used in this study. Our results showed that increasing concentrations of neopterin does not have any significant effects on the cytotoxicity while as expected the three other agents decrease the viability of all subjected cell lines. SNU-449 is the most resistant HCC cell line among others. Considering the effectivity of combinational therapy in cancer patients, the effect of various combinations of neopterin with doxorubicin, cisplatin and vitamin C on the viability of the most resistant cell line of SNU-449 has been investigated. We found that the addition of cisplatin to the combination of neopterin and vitamin C, causes a greater decrease in cell viability of SNU-449 cells compared to the dual therapy with neopterin and vitamin C, while the addition of doxorubicin to the same dual therapy, leads to a decrease in the effectivity of it.